Close this search box.
Trending now:  
Improved Clinical Outcomes with Intravascular Imaging-Guided PCI: Impact of Standardized Optimization Protocols
Influence of Chest Compression Duration on Pediatric In-Hospital Cardiac Arrest Survival
Gender Disparities in Outcomes of Invasive versus Conservative Strategies for Coronary Artery Disease: Insights from the ISCHEMIA Trial
RELIEVE-HF: Interatrial shunt in patients with heart failure
Expedited transfer to cardiac arrest center vs standard care for non-ST elevation out-of-hospital cardiac arrest

Content for healthcare professionals only

News |

ESC Congress 2023 Highlights

29 Aug 2023
ESC 2023 Highlights

The European Society of Cardiology (ESC) held its 46th annual congress August 25-29, 2023 in Amsterdam, Netherlands. Here is our curated list of the top 13 sessions.

STEP HFpEF (NCT04788511) explored if semaglutide could be used to target obesity-related heart failure with preserved ejection fraction (HFpEF). Investigators randomized 529 adult patients with HFpEF and obesity to receive either once weekly semaglutide (n=263) or placebo (n=266). Patients receiving semaglutide showed a greater change in Kansas City Cardiomyopathy Questionnaire clinical summary scores at 52 weeks than placebo. Semaglutide was also associated with a greater change in body weight than placebo. Patients taking semaglutide showed greater reductions in C-reactive protein levels than patients on placebo. Patients taking semaglutide also improved their 6-minute walk distance (6MWD) to a greater degree than patients on placebo.

NOAH-AFNET 6 (NCT02618577) explored if edoxaban could prevent stroke or cardiovascular (CV) death in patients with atrial high rate episodes. A composite of CV death, stroke or systemic embolism comprised the primary endpoint. A composite of death from any cause or major bleeding comprised the....

To read full highlights article please login or sign up as a member.


Related Topics

Related Articles